Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)

 

Chemotherapy in Advanced Bronchioloalveolar Carcinoma (BAC)
Author
Howard (Jack) West, MD

Up until very recently, conclusions about the usefulness of chemotherapy among patients with advanced, diffuse BAC had generally been based on retrospective experiences with chemotherapy at a single center with a very limited number of patients. From such limited subsets, it is difficult to tell whether BAC is less responsive to standard chemotherapy than other forms of NSCLC, as is widely perceived, or if chemo is similarly helpful for BAC as for NSCLC in general. Some of these studies suggest a similar response rate in BAC compared to other types of NSCLC, while others suggest that patients with BAC are less likely to respond. Making conclusions has also been a problem because of the difficulty in measuring response of BAC lesions, which are often poorly circumscribed on CT scans that are generally used for response assessment.

The Southwest Oncology Group (SWOG) conducted the first prospectively designed trial for patients with advanced BAC, S9714 (abstract here). This trial included 58 chemo-naïve patients with advanced stage BAC who received a four-day long infusion of taxol (paclitaxel) repeated every 3 weeks. The response rate of 14% and survival averaging a year were accompanied by significant toxicity, with infections and nerve damage, that limited interest in future study of this approach. Another trial done in Europe also tested taxol in advanced BAC, this one using a more common schedule of giving it one day every three weeks (EORTC Taxol in BAC abstract here). The response rate was only 11%, and many patients progressed off of this chemo in just a couple of months, and overall these results were disappointing. Taken together with the retrospective studies, it appears that while conventional chemotherapy may possibly be as good as that seen with NSCLC in general, but since patients with BAC on average have a slower progression than do patients with other types of NSCLC, it was clear that other approaches were needed.

The study of BAC is still in the early stages, and it’s fair to say that we really haven’t tested many types of chemotherapy well in BAC. I and other people have seen encouraging responses of BAC patients with several kinds of chemotherapy, including Alimta (pemetrexed), which is being studied in a clinical trial by SWOG (SWOG 0526)available at many sites throughout the country. In addition, we’ve seen clear activity in BAC with targeted therapies, specifically EGFR tyrosine kinase inhibitors, that have been very encouraging and are described in a separate post.

Next Previous link

Previous PostNext Post

Related Content

Article
Advance directives are a powerful way to take control of healthcare choices. These documents allow you to outline preferences for medical care and specify end-of-life wishes. These documents can also be a way to appoint loved ones who you would like to help with these decisions, such as a healthcare proxy (someone to make decisions on your behalf, if you cannot). As cancer treatments can involve aggressive treatments and/or complex medical management, having advance directives ensures that your desires regarding treatment options and end-of-life care are clearly communicated. 
Image
2024-25 patient perspectives header
Article
Tell your story and help us help others! Apply online now for this paid opportunity. This program gives a voice to those who have experience in participating in a clinical trial for a cancer diagnosis. Your voice helps to educate and advocate for others who are in or who may be considering a clinical trial.  We want to hear from you!
Image
Foro de Pacientes de Terapias Dirigidas de Cáncer de Pulmón
Video
¡El vídeo completo bajo demanda está disponible para verlo!

Forum Discussions

Hi elysianfields and welcome to Grace.  I'm sorry to hear about your father's progression. 

 

Unfortunately, lepto remains a difficult area to treat.  Recently FDA approved the combo Lazertinib and Amivantamab...

Hello Janine, thank you for your reply.

Do you happen to know whether it's common practice or if it's worth taking lazertinib without amivantamab? From all the articles I've come across...

Hi elysianfields,

 

That's not a question we can answer. It depends on the individual's health. I've linked the study comparing intravenous vs. IV infusions of the doublet lazertinib and amivantamab...

Recent Comments

JOIN THE CONVERSATION
That's beautiful Linda…
By JanineT GRACE … on
I could not find any info on…
By JanineT GRACE … on
Hi elysianfields,

 

That's…
By JanineT GRACE … on
Hello Janine, thank you for…
By elysianfields on